Explore more publications!

Colombia Protests Trump’s Drug Trafficking Allegations Against Petro

(MENAFN) Colombia’s foreign minister announced Tuesday that the country had delivered a formal letter of protest to the United States after President Donald Trump accused his Colombian counterpart of involvement in drug trafficking.

At a press briefing, Rosa Villavicencio stated she would meet with U.S. charge d’Affaires John McNamara to present a "(diplomatic) note, rejecting these insults, threats" directed at President Gustavo Petro.

Emphasizing that Petro is Colombia’s democratically elected leader, she stressed that "an offence against the president is an offence to our country and a disregard for all the democratic processes that we have carried out."

Villavicencio’s comments followed Trump’s direct warning to Petro, in which he accused him of being a drug trafficker.

Speaking to journalists aboard Air Force One, Trump remarked that a possible operation against Colombia "sounds good to me."

He described Colombia as a "very sick" nation led by a "sick man," alleging—without evidence—that Petro was engaged in "making cocaine and selling it to the United States."

Trump added that Petro "is not going to be doing it very long."

President Petro has firmly rejected these accusations, insisting he has never been involved in drug trafficking.

MENAFN07012026000045017167ID1110566903


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions